609367-41-1

Upstream product

• 609367-28-4 ((S)-1-Dimethylcarbamoyl-2-hydroxy-2-methyl-propyl)-carbamic acid benzyl ester 
• 112110-89-1 N-[(Phenylmethoxy)carbonyl]-L-β-hydroxyvaline 
• 102507-13-1 N-(tert-butoxycarbonyl)-3-hydroxy-L-valine 
• 1422130-07-1 N²-(tert-butoxycarbonyl)-3-hydroxy-N,N-dimethyl-L-valinamide 
• 1422130-08-2 3-hydroxy-N,N-dimethyl-L-valinamide hydrochloride 

Downstream Products

• 609367-08-0 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid ((S)-1-dimethylcarbamoyl-2-hydroxy-2-methyl-propyl)-amide 
• 1422128-71-9 C₂₅H₃₀F₆N₄O₃S 

Relevant academic research and scientific papers

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a novel compound having a superior activity as an ERR-alpha modulator and useful as an agent for the prophylaxis or treatment of ERR-alpha associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof

Structure-activity relationships of the peptide deformylase inhibitor BB-3497: Modification of the P2′ and P3′ side chains

Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2′ and P3′ side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2′ and P3′ positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2′ and P3′ positions to optimise the physicochemical properties.